3 results
The primary objective is to determine the pharmacokinetic characteristics of galantamine after 2 single oral doses in children with Down syndrome. Secondary objectives are to evaluate safety and tolerability.
To demonstrate the bioequivalence of sorafenib with probenecid relative to sorafenib without probenecid based on the AUC in patients with unresectable hepatocellular cancer, advanced clear-cell renal cell carcinoma, locally recurrent or metastatic,…
I will test the hypothesis that the noradrenergic system amplifies tremulous activity in the cerebello-thalamo-cortical circuit. More specifically, I will test how this modulation takes place (i.e. through which brain regions and connections).